Karolina Anderson, MD
Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1417319369
Payments from drug & device makers
Across 449 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Xeris Pharmaceuticals, Inc.$673
- Insulet Corporation$499
- Sanofi-aventis U.S. LLC$498
- Cequr Corporation$478
- plus $5K from 35 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $1,168 |
| Lilly USA, LLC | 53 | $1,071 |
| Xeris Pharmaceuticals, Inc. | 31 | $673 |
| Insulet Corporation | 27 | $499 |
| Sanofi-aventis U.S. LLC | 25 | $498 |
| Cequr Corporation | 3 | $478 |
| Amgen | 25 | $475 |
| Bayer | 17 | $352 |
| Averitas Pharma Inc. | 14 | $329 |
| BETA Bionics, Inc. | 11 | $279 |
| Sequel Med Tech, LLC | 9 | $278 |
| Radius Health, Inc. | 13 | $258 |
| Dexcom, Inc. | 24 | $251 |
| Corcept Therapeutics | 10 | $232 |
| Medtronic | 7 | $222 |
| Mannkind Corporation | 8 | $206 |
| AbbVie | 10 | $179 |
| AstraZeneca(2 entities) | 9 | $172 |
| Abbott | 23 | $151 |
| Chiesi USA, Inc. | 7 | $150 |
| Boehringer Ingelheim | 7 | $136 |
| Kyowa Kirin, Inc. | 7 | $133 |
| Tandem Diabetes Care, Inc. | 4 | $121 |
| IBSA Pharma Inc. | 6 | $100 |
| Pfizer | 4 | $97 |
| Ascensia Diabetes Care US Inc. | 4 | $91 |
| Antares Pharma, Inc. | 5 | $91 |
| Ultragenyx Pharmaceutical Inc. | 3 | $84 |
| Novartis | 4 | $82 |
| Neurocrine Biosciences, Inc. | 3 | $80 |
| Ascendis Pharma Endocrinology Inc | 4 | $76 |
| Amphastar Pharmaceuticals, Inc. | 3 | $62 |
| Amneal Pharmaceuticals LLC | 3 | $60 |
| Rhythm Pharmaceuticals, Inc. | 2 | $41 |
| Recordati_rare_diseases_inc. | 2 | $40 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Acella Pharmaceuticals, LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $19 |
| Halozyme Inc | 1 | $19 |
| Nevro Corp. | 1 | $13 |
How this compares
$9,335 in reported general payments places this provider in the 60th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Nashville
- Stephen SharpNashville$25.9M
- Kathryn DahirNashville$11M
- Craig WierumNashville$1.7M
- Terri JerkinsNashville$1.2M
- Shichun BaoNashville$735K
- Michael MayNashville$689K
- Michael CarlsonNashville$381K
- Rodney SnowNashville$188K
- Kevin NiswenderNashville$100K
- Howard BaumNashville$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.